Paclitaxel belongs to cell inhibitor drugs. It is the most impressive anti-breast cancer star. Attacked by paclitaxel generics and their derivatives docetaxel, taxol steps into the slow recession in foreign markets. Docetaxel with its excellent mechanism, coupled with the chemical patent escort, thus has a good market in the world. Taxotere has been the best in the global anticancer drugs, only after myeloid leukemia therapy drug gleevec. It accounts for 10% of the anticancer drug market in the world's top 500.

In recent years, studies found that docetaxel has also got encouraging progress in clinical trials for other solid tumors. Resveratrol market implies a huge opportunity. Many R & D institutions, manufacturers in droves, many pharmaceutical companies to follow up the report registered more than docetaxel. In 2007, China 16 cities in the sample hospital medication Statistical data show that paclitaxel and docetaxel are the first two species living in anti-tumor market. Paclitaxel drug amount of 364.34 million RMB, up 22.84 percent the previous year; the docetaxel medication amount of 339.32 million RMB, up 38.52 percent the previous year. The first half of 2008, docetaxel was similar drugs accounted for 5.43 percent, 0.22 percentage points less than a paclitaxel alone.

Since 2002, docetaxel has maintained a high growth trend, the compound annual growth rate of 88.5 percent, much higher than similar varieties. Although the total sales are still lagging behind the paclitaxel, but because of the rapid growth of sales to catch up with taxol just around the corner. Docetaxel in the first half of 2008 accounted for 50.33% of the market share of docetaxel. 2008 year-on-year increase of 19 percent, ranking Taxotere 2.

Anastrozole is a potent selective triazole aromatase inhibitors, can inhibit the cytochrome P-450 dependent aromatase, thereby blocking estrogen biosynthesis, estrogen to stimulate breast cancer cell growth the main factor. Indications for breast cancer, especially suitable for the use of hormonal adjuvant therapy after the recurrence of menopause women with advanced breast cancer. The global market share of $ 1.73 billion in 2007, the year-on-year increase of 14.72% in 2008 has reached 18.57 percent, up 7.34 percent the previous year. Letrozole by inhibiting aromatase, estrogen levels decline, thus eliminating the stimulating effect of estrogen on tumor growth, especially in postmenopausal breast cancer patients.

Derivatives, to replace surgery and radiotherapy treatment of premenopausal breast cancer chemotherapies. Its mechanism of action is to reduce the secretion of LH and FSH, so that lower estrogen levels and breast cancer, prostate cancer and endometriosis lesions improved. Variety of goserelin is developed by astrazeneca for the treatment of chia seed endometriosis, breast cancer, prostate cancer. The global market share in 2008 was $ 1.138 billion, an increase of nearly 3.07% more than the $ 1.104 billion in 2007. 1999, goserelin injection into the Chinese market, its slow-release implants approved in 2004 for clinical use in China, the domestic drugs not listed.

Leuprolide is a highly active LH-RH derivative. Leuprolide’s resistance to proteolytic enzymes and LH-RH receptor affinity are stronger than LH-RH. It is able to effectively suppress pituitary gonadal function of the system. For endometriosis, uterine fibroids, or pre-menopausal breast cancer patients, it has a good effect mainly for clinical prostate cancer and endometriosis. LH-RH analogues are not only used for the treatment of breast cancer. Its important indications are prostate cancer and endometriosis disease. In view of market composition, currently they are dominated by foreign and joint ventures. So the drug price is a litter higher, and antineoplastic price reduction list have not seen its shadow. It can be predicted that sales of the drugs will increase year by year.Source:http://www.cospcn.com